ENANTA PHARMACEUTICALS INC - Common Stock (ENTA)

Q3 2014 13F Holders as of 9/30/2014

Type / Class: Equity / Common Stock
Shares outstanding: 21.5M
Number of holders: 109
Total 13F shares, excl. options: 9.99M
Shares change: +1.64M
Total reported value, excl. options: $395M
Value change: +$64.4M
Put/Call ratio: 2.52
Number of buys: 69
Number of sells: -38
Price: $39.57

Significant Holders of ENANTA PHARMACEUTICALS INC - Common Stock (ENTA) as of Q3 2014

122 filings reported holding ENTA - ENANTA PHARMACEUTICALS INC - Common Stock as of Q3 2014.
ENANTA PHARMACEUTICALS INC - Common Stock (ENTA) has 109 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 9.99M shares of 21.5M outstanding shares and own 46.58% of the company stock.
Largest 10 shareholders include FMR LLC (2.01M shares), Consonance Capital Management LP (1.6M shares), EAGLE ASSET MANAGEMENT INC (926K shares), SENZAR ASSET MANAGEMENT, LLC (567K shares), Marshall Wace LLP (316K shares), RA CAPITAL MANAGEMENT, LLC (250K shares), BlackRock Fund Advisors (249K shares), VANGUARD GROUP INC (242K shares), GUGGENHEIM CAPITAL LLC (205K shares), and WALL STREET ASSOCIATES (159K shares).
This table shows the top 109 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

Investor	Option	Weight %	Change %	Value $	* Price $	Shares	Share Change	Activity	Report Period

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.